DEFEAT CANCER
NETRIS Pharma is dedicated to defeat cancer through novel and unique approach targeting Dependence Receptors
A Unique Environment to Develop Innovative Therapeutics
NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.
Our news
03/29/2023
NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137
03/06/2023
NETRIS Pharma publishes new article "From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors" published in EMBO Molecular Medicine - March 6th, 2023
01/26/2023
NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
Our publications
03/06/2023
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors
04/04/2022
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
03/11/2022
Δ40p53 isoform up-regulates netrin-1/UNC5B expression and potentiates netrin-1 pro-oncogenic activity
A Strategic Focus on Intellectual Property Rights
As the world pioneer and leader biotech company targeting ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach and activity.
Our partners
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate partners.
Clinical
Corporate
Research
